Compare Crispr Therapeutics AG (CRSP) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Xcel Energy Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Xcel Energy Inc trades at $80.32 (market cap $50.05B). The key difference: Xcel Energy Inc is far larger — about 10.1× Crispr Therapeutics AG's market cap, and Xcel Energy Inc pays a 2.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | XEL | |
|---|---|---|
Market Cap | $4.97B | $50.05B |
Sector | Health | Utilities |
52-Week High | $76.78 | $83.91 |
52-Week Low | $44.34 | $68.33 |
Enterprise Value | $3.32B | $87.49B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
XEL trades at $80.48, up 0.52% today, with a bullish technical signal and strong analyst consensus. Recent earnings show a Q1 2026 beat, while Q3 and Q4 2025 missed expectations. The company's $60 billion capital plan through 2030 aims to capitalize on rising electricity demand, supporting projected EPS growth. Cash flow trends show improving net cash flow, reaching $637 million in 2026. The stock is near its 52-week high, with a consensus price target of $91.88 implying potential upside.
Outlook is positive due to robust capital investment and sector tailwinds, but regulatory pushback and high valuation pose risks. Analyst sentiment is predominantly bullish, with 63% buy ratings. Investors should weigh growth prospects against execution risks and current premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
